Ezetimibe (Zetia) Guideline‑Based Dosing and Clinical Use
Combination with Statins
- For high‑risk patients who need additional LDL‑C lowering beyond a maximally tolerated statin, co‑administering ezetimibe 10 mg at the same time as the statin is the preferred approach. [Praxis Medical Insights] 1, 2
Indications for Adding Ezetimibe
- In very high‑risk secondary‑prevention patients, add ezetimibe 10 mg when LDL‑C remains ≥ 70 mg/dL (1.8 mmol/L) despite maximally tolerated statin therapy. [Praxis Medical Insights] 1, 2
Use in Statin‑Intolerant Patients
- For patients who cannot tolerate statins, ezetimibe 10 mg as monotherapy reduces LDL‑C by ≈ 18–20 % and is recommended as the first‑line non‑statin option. [Praxis Medical Insights] 1, 2
Sequencing Before PCSK9 Inhibitors
- Guidelines mandate that ezetimibe be trialed before escalating to PCSK9 inhibitors because it is cost‑effective and a required step in the treatment algorithm. [Praxis Medical Insights] 1
Safety Monitoring with Statin Combination
- When ezetimibe is combined with a statin, monitor liver enzymes and creatine kinase according to standard statin monitoring recommendations; ezetimibe adds only a minimal increase in muscle‑related discontinuations (1.1 % vs 0.6 % with statin alone). [Praxis Medical Insights] 2
Pediatric Initiation Age
- For children with familial hypercholesterolemia who have not reached LDL‑C targets with lifestyle measures alone, initiate a statin + ezetimibe regimen between 8 – 12 years of age. [Canadian Journal of Cardiology] 3